Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks rose Friday as oil rebounded, with markets posting three positive sessions in a row for solid weekly gains, their biggest since October.
The company’s drug delivery system is comprised of a thin film wafer, which is placed on the top floor of the tongue, and is retained at the site of application, rapidly releasing a variety of opioids such as morphine and codeine, as well as narcotics such as marijuana.
Threshold Pharmaceuticals had its “buy” rating and $12 target price reiterated at HC Wainwright, which said the biotechnology company’s investigational anticancer drug TH-302 appears poised to advance in Myeloma. HCW said that at the ongoing ASH meeting in San Francisco last weekend, Threshold presented data from Part C of its Phase 1/2 study of TH-302 in relapsed/refractory multiple myeloma.
M Pharmaceutical announces sweeping changes as business focus moves to biomedical device for diabetics
M Pharmaceutical has changed its name from First Sahara Energy (CSE:FSE) to better suit its new business focus in the pharmaceutical and biomedical device markets, and has already signed a preliminary agreement to license a new blood glucose monitoring device for diabetics.
Nanobiotix has agreed a significant funding deal with a US investor that will broaden the scope of development of its ground-breaking advance on traditional radiotherapy.
U.S. stocks edged up amid thin volumes Wednesday after a deluge of data, including a spike in initial jobless claims, a jump in durable goods and lower-than-anticipated consumer spending and new home sales. Both the S&P 500 and the Dow managed to clinch new records.
Investors interested in Neuralstem recently viewed
- Advanced Oncotherapy (AIM: AVO) New technology for innovative and patient-focused cancer treatments
- ReNeuron (AIM: RENE) Leading stem cell company targeting areas of significant unmet medical need
- Alliance Pharma (AIM: APH) Prescription branded medicines in the human medical and dental sectors
- Cellmid (ASX: CDY) Cellmid is the world leader in Midkine Intellectual Property
- Admedus (ASX: AHZ) Making a difference in Healthcare